<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1988">
  <stage>Registered</stage>
  <submitdate>30/05/2008</submitdate>
  <approvaldate>30/05/2008</approvaldate>
  <nctid>NCT00688597</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate the Safety of AT2220 in Pompe Disease</studytitle>
    <scientifictitle>An Open-Label, Multicenter, Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Three Dosing Regimens of Oral AT2220 in Patients With Pompe Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>POM-CL-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pompe Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AT2220
Treatment: drugs - AT2220
Treatment: drugs - AT2220

Experimental: Cohort 1 - AT2220 low dose, regimen 1, for 11 weeks

Experimental: Cohort 2 - AT2220 high dose, regimen 1, for 11 weeks

Experimental: Cohort 3 - AT2220 high dose, regimen 2, for 11 weeks


Treatment: drugs: AT2220
low dose regimen 1
powder in a bottle for dissolution in water for oral administration

Treatment: drugs: AT2220
high dose, regimen 1

Treatment: drugs: AT2220
high dose, regimen 2

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment-emergent Adverse Events</outcome>
      <timepoint>11 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in functional parameters from Baseline to End of Study</outcome>
      <timepoint>11 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Male or female, 18 to 74 years of age inclusive

          2. Diagnosis of Pompe disease based on clinical assessment, enzyme assay, and/or
             genotyping. Confirmatory genotyping will be performed on all subjects who are screened
             for the study.

          3. Naïve to ERT or has not received ERT in the 3 months prior to screening

          4. Willing not to initiate ERT or other prohibited treatment during study participation

          5. Functional grade for arms and/or legs =2 OR sitting FVC =30% and &lt;80% of predicted
             value, reproducible between visits 1 and 2 (± 15%)

          6. Subjects of reproductive potential agree to use reliable methods of contraception
             during the study

          7. Subject or legal representative is willing and able to provide written informed
             consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>74</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Any intercurrent condition that may preclude accurate interpretation of study data

          2. Obstructive pulmonary disease

          3. Invasive ventilatory support

          4. Use of noninvasive ventilatory support &gt;8 hours/day while awake

          5. History of QTc prolongation &gt;450 msec for males and &gt;470 msec for females

          6. History of allergy or sensitivity to the study drug, including any prior serious
             adverse reaction to iminosugars (e.g., miglustat, miglitol)

          7. Pregnancy or breast-feeding

          8. Current or recent drug or alcohol abuse

          9. Treatment with another investigational drug within 30 days of study start

         10. Use of prohibited medications =3 months prior to screening

         11. Otherwise unsuitable for the study in the opinion of investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>3</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Women's and Children's Hospital - North Adelaide</hospital>
    <postcode>5006 - North Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bremen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Salford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amicus Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this study is to determine the safety and tolerability of three different
      doses of AT2220 in people affected by Pompe disease. The study will also evaluate the effects
      of AT2220 on functional parameters in Pompe disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00688597</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mathews Adera, MD</name>
      <address>Amicus Therapeutics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>